Welcome to this week’s edition of top stock market highlights.
This week spans the local and the global: a fresh cost-of-living pinch for Singapore households as power and gas tariffs climb, a landmark healthcare debut set for the SGX mainboard, and a sharp share-price reaction in the US that defied a strong operational showing.
Here is what caught our eye.
Higher fuel costs push power and gas bills up for households
Singapore households face steeper utility bills this quarter.
The Energy Market Authority (EMA) said on 30 June 2026 that the electricity tariff will rise 17% and the town gas tariff by 7.1% from July to September 2026.
Grid operator SP Group said electricity prices for homes will climb 4.64 cents per kilowatt-hour (kWh) from the previous quarter, to 31.91 cents per kWh, before goods and services tax.
A four-room Housing & Development Board household can expect an increase of around S$17.14 in its average monthly electricity bill before GST.
Piped gas provider City Energy will lift its household tariff by 1.56 cents per kWh, to 23.48 cents per kWh, before GST.
The EMA attributed the increase to higher natural gas prices amid the Middle East conflict, though it flagged that tariffs could ease in the fourth quarter should the situation improve.
Listed players Sembcorp Industries (SGX: U96) and Keppel (SGX: BN4) have power-generation exposure here.
Temasek-backed specialist network heads for a S$1 billion SGX debut
Foundation Healthcare Holdings, a private healthcare group backed by Temasek’s SeaTown, lodged a preliminary prospectus for a mainboard listing on the Singapore Exchange and has since priced its offering.
The company priced its IPO at S$0.76 a share, the floor of its S$0.76 to S$0.92 range, raising around S$242 million and valuing the group near S$1 billion — the largest healthcare IPO since IHH Healthcare‘s (SGX: Q0F) 2012 dual-listing.
Trading is expected to begin on 8 July 2026.
Founded in 2023, the group has grown rapidly via acquisitions: revenue rose from S$112.4 million in FY2023 to S$231.2 million in FY2025, while group profit climbed from S$7.3 million to S$41.2 million over the same period.
By March 2026 it ran 108 specialists across 74 clinics and four medical centres.
Proceeds fund further acquisitions and expansion into Malaysia and Hong Kong; notably, no dividend is planned for FY2026 or FY2027.
Over in the US, Tesla‘s (NASDAQ: TSLA) shares tumbled despite a delivery beat.
